SEOM‑GEMCAD‑TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)

• Carles Pericay ^[3] ; Clara Montagut ^[1] ; Juan José Reina ^[4] ; Marcos Melian ^[5] ; Julia Alcaide ^[6] ; Noelia Tarazona ^[7] ; Ana Ruiz Casado ^[8] ; Encarnación González Flores ^[9] ; Begoña Graña ^[10] ; Cristina Grávalos ^[2]
  1. [1] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  2. [2] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  3. [3] Medical Oncology Department, Hospital University, Mútua de Terrassa, Barcelona, Spain
  4. [4] Medical Oncology Department, Hospital University, Virgen Macarena, Seville, Spain
  5. [5] Medical Oncology Department, IVO, Valencia, Spain
  6. [6] Medical Oncology Department, Hospital University, Regional y Virgen de la Victoria, Málaga, Spain
  7. [7] Medical Oncology Department, Hospital Clínico University de Valencia, Valencia, Spain
  8. [8] Medical Oncology Department, H.U. Puerta de Hierro, Madrid, Spain
  9. [9] Medical Oncology Department, Hospital University, Virgen de las Nieves, Granada, Spain
  10. [10] Medical Oncology Department, Complexo Hospitalario Universitario, A Coruña, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2812-2825
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Colorectal cancer (CRC) has a 5-year overall survival rate of over 60%. The decrease in the rate of metastatic disease is due to screening programs and the population’s awareness of healthy lifestyle. Similarly, advancements in surgical methods and the use of adjuvant chemotherapy have contributed to a decrease in the recurrence of resected disease. Before evaluating a patient’s treatment, it is recommended to be discussed in a multidisciplinary tumor board. In stage II tumors, the pathologic characteristics of poor prognosis must be known (T4, number of lymph nodes analyzed less than 12, lymphovascular or perineural invasion, obstruction or perforation, poor histologic grade, presence of tumor budding) and it is mandatory to determine the MSI/MMR status for avoiding administering fuoropyridimidines in monotherapy to patients with MSI-H/ dMMR tumors. In stage III tumors, the standard treatment consists of a combination of fuoropyrimidine (oral or intravenous) with oxaliplatin for 6 months although the administration of CAPOX can be considered for 3 months in low-risk tumors. Neoadjuvant treatment is not consolidated yet although immunotherapy is achieving very good preliminary results in MSI-H patients. The use of ctDNA to defne the treatment and monitoring of resected tumors is only recommended within studies. These guidelines are intended to help decision-making to ofer the best management of patients with non-metastatic colon cancer.